5-bromo-1-methyl-3-(5-morpholin-4-yl-pyridin-2-ylamino)-1H-pyridin-2-one | 1178884-46-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-bromo-1-methyl-3-(5-morpholin-4-yl-pyridin-2-ylamino)-1H-pyridin-2-one
• 英文别名: 5-bromo-1-methyl-3-(5-morpholinopyridin-2-ylamino)pyridin-2(1H)-one；5-bromo-1-methyl-3-[(5-morpholin-4-ylpyridin-2-yl)amino]pyridin-2-one
• CAS: 1178884-46-2
• 化学式: C₁₅H₁₇BrN₄O₂
• 分子量: 365.23
• InChiKey: GJWASXTXALQWPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0^2,6]dodeca-1(8),2(6)-dien-10-yl}-4-fluoro-6-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methyl acetate 、 5-bromo-1-methyl-3-(5-morpholin-4-yl-pyridin-2-ylamino)-1H-pyridin-2-one 、 以277 mg of 256a was obtained as a yellow solid (53%)的产率得到(2-{4,4-dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.0(2,6)]dodeca-1(8),2(6)-dien-10-yl}-4-fluoro-6-(1-methyl-5-{[5-(morpholin-4-yl)pyridin-2-yl]amino}-6-oxo-1,6-dihydropyridin-3-yl)phenyl)methyl acetate
  参考文献：
  名称：

  PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE

  摘要：

  本发明提供公式I的吡啶酮和氮杂吡啶酮化合物，包括立体异构体、互变异构体和其医药上可接受的盐，用于抑制Btk激酶并治疗由Btk激酶介导的免疫紊乱，例如炎症。本发明还公开了使用公式I化合物在哺乳动物细胞中进行体外、原位和体内诊断和治疗此类疾病或相关病理条件的方法。

  公开号：

  US20120010191A1
• 作为产物：
  描述：

  tert-butyl 4-(6-((5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino)pyridin-3-yl) piperazine-1-carboxylate 、 3,5-二溴-1-甲基吡啶-2(1H)-酮 、 5-(4-吗啉)-2-吡啶胺 以255c was obtained as a yellow solid (986 mg, 63%)的产率得到5-bromo-1-methyl-3-(5-morpholin-4-yl-pyridin-2-ylamino)-1H-pyridin-2-one
  参考文献：
  名称：

  PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE

  摘要：

  本发明提供公式I的吡啶酮和氮杂吡啶酮化合物，包括立体异构体、互变异构体和其医药上可接受的盐，用于抑制Btk激酶并治疗由Btk激酶介导的免疫紊乱，例如炎症。本发明还公开了使用公式I化合物在哺乳动物细胞中进行体外、原位和体内诊断和治疗此类疾病或相关病理条件的方法。

  公开号：

  US20120010191A1

文献信息

• Inhibitors of Bruton's Tyrosine Kinase
  申请人：Berthel Steven

  公开号：US20100222325A1

  公开（公告）日：2010-09-02

  This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y 1 , Y 2 , Y 2′ , Y 3 , Y 4 , Y 5 , m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

  该应用程序根据通用公式I-III披露了5-苯基-1H-吡啶-2-酮，6-苯基-2H-吡啶-3-酮和5-苯基-1H-吡嗪-2-酮衍生物： 其中，变量Q、R、X、X'、Y1、Y2、Y2'、Y3、Y4、Y5、m和n的定义如本文所述，这些化合物抑制Btk。本文披露的化合物对调节Btk的活性并治疗与过度Btk活性相关的疾病有用。这些化合物进一步有助于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，如类风湿性关节炎。还披露了含有公式I-III化合物和至少一种载体、稀释剂或赋形剂的组合物。
• [EN] PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIDONE ET D'AZA-PYRIDONE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GILEAD CONNECTICUT INC

  公开号：WO2011140488A1

  公开（公告）日：2011-11-10

  Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  提供了公式I的吡啶酮和氮杂吡啶酮化合物，包括其立体异构体、互变异构体和药学上可接受的盐，用于抑制Btk激酶，并用于治疗由Btk激酶介导的炎症等免疫紊乱。公开了使用公式I化合物进行体外、原位和体内诊断以及治疗哺乳动物细胞中的这类紊乱或相关病理条件的方法。
• [EN] NOVEL PYRIDINONES AND PYRIDAZINONES<br/>[FR] NOUVELLES PYRIDINONES ET PYRIDAZINONES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009098144A1

  公开（公告）日：2009-08-13

  This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one deriva-tives according to generic Formulae I-III : wherein, variables R, X, Y1, Y2, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat in-flammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

  该应用程序披露了根据通用公式I-III导出的5-苯基-1H-吡啶-2-酮和6-苯基-2H-吡啶嗪-3-酮衍生物：其中，变量R、X、Y1、Y2、Y3、Y4、n和m的定义如本文所述，在抑制Btk。本文披露的化合物可用于调节Btk的活性并治疗与过度Btk活性相关的疾病。这些化合物进一步可用于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，如类风湿性关节炎。还披露了含有公式I-III化合物和至少一种载体、稀释剂或赋形剂的组合物。
• Inhibitors of Bruton's tyrosine kinase
  申请人：Dewdney Nolan James

  公开号：US20090306041A1

  公开（公告）日：2009-12-10

  This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-III: wherein, variables R, X, Y 1 , Y 2 , Y 3 , Y 4 , n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

  本申请披露了根据通用式I-III公式的5-苯基-1H-吡啶-2-酮和6-苯基-2H-吡嗪-3-酮衍生物：其中，变量R、X、Y1、Y2、Y3、Y4、n和m的定义如本文所述，它们抑制Btk。本文所披露的化合物有助于调节Btk的活性并治疗与过度Btk活性相关的疾病。此外，这些化合物还有助于治疗与异常B细胞增殖相关的炎症和自身免疫性疾病，如类风湿性关节炎。还披露了含有公式I-III化合物和至少一种载体、稀释剂或赋形剂的组合物。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Roche Palo Alto LLC

  公开号：US20140194413A1

  公开（公告）日：2014-07-10

  This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: wherein, variables R, X, Y 1 , Y 2 , Y 2′ , Y 3 , Y 4 , n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-IV and at least one carrier, diluent or excipient.

  本申请公开了根据通用式I-IV所述的5-苯基-1H-吡啶-2-酮和6-苯基-2H-吡嗪-3-酮衍生物：其中，变量R、X、Y1、Y2、Y2'、Y3、Y4、n和m的定义如本文所述，这些衍生物抑制Btk。本文所披露的化合物有用于调节Btk活性并治疗与过度Btk活性相关的疾病。这些化合物进一步有助于治疗与异常B细胞增殖相关的炎症和自身免疫性疾病，如类风湿性关节炎。还公开了包含通用式I-IV化合物和至少一种载体、稀释剂或赋形剂的组合物。